# US 2013/0212721 A1 · Reagent for tumor testing and pharmaceutical composition for tumor prevention

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0212721 A1
- Document ID: US20130212721A1
- Status: Published application
- Kind: A1
- Application number: 13/817,005
- Filed: 2011-08-15
- Published: 2013-08-15
- Earliest claimed: 2010-08-16
- Assignees: Kyushu University, National University Corporation
- Inventors: Atsushi Takahashi
- Web page: https://patentgrep.com/patent/US20130212721A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/13: B-cells
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/30: from tumour cells
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57525: of the liver or pancreas
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- A01K 2217/052: inducing gain of function
- A01K 2227/105: Murine
- A01K 2267/0331: Animal model for proliferative diseases
- C12N 2310/14: interfering nucleic acids [NA]
- C12Q 2563/131: the label being a member of a cognate binding pair, i.e. extends to antibodies, haptens, avidin
- C12Q 2600/158: Expression markers
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention aims to provide a novel reagent for tumor testing and a novel pharmaceutical composition for tumor prevention. The present invention provides a reagent for tumor detection, which comprises a probe for the FEAT gene or amplification primers for the FEAT gene, or an antibody against the FEAT protein or a fragment of the antibody. Moreover, the present invention also provides a pharmaceutical composition for tumor prevention, which is configured to use the FEAT gene or the FEAT protein as a tumor marker to thereby recognize tumor cells.

## Claims

### Claim 1

A reagent for tumor detection, which comprises a probe for the FEAT gene or amplification primers for the FEAT gene, or an antibody against the FEAT protein or a fragment of the antibody.

### Claim 2

A pharmaceutical composition for tumor prevention, which comprises a substance shown in (a) or (c) below or cells shown in (b) below:
(a) a substance capable of inhibiting FEAT gene expression or FEAT protein activity;
(b) immune cells capable of reacting with the FEAT protein; or
(c) a substance capable of binding to the FEAT protein, which substance carries an antitumor agent, the substance shown in (a) above or the cells shown in (b) above.

### Claim 3 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the substance capable of inhibiting FEAT gene expression is siRNA against the FEAT gene.

### Claim 4 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the substance capable of inhibiting FEAT protein activity is an antibody against the FEAT protein.

### Claim 5 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the immune cells are T cells, B cells or dendritic cells.

### Claim 6 (depends on 1)

A method for tumor detection, which comprises reacting a test sample taken from a living body with the reagent according to claim 1.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the test sample is blood, a body fluid or a tissue section.

### Claim 8

A tumor animal model, which consists of a transgenic non-human animal transformed with the FEAT gene.
